A multicenter, non-interventional study to observe the safety and efficacy of Vedolizumab in bio-naïve patients suffering from Crohn’s disease or ulcerative colitis, observed in daily practice in Austria: Results of the CHRONOS study1 1NCT02986724, Study Sponsor: Takeda

Background Exploratory analysis of the pivotal phase 3 GEMINI studies for Vedolizumab suggested that patients who are naïve to TNF-α antagonist therapy show a better response on vedolizumab treatment than patients who already failed on one or more TNF-α antagonist therapies. In this context CHRONOS was designed to provide real-world-data on the effectiveness and safety of vedolizumab in bio-naïve patients suffering from Crohn’s disease (CD) or ulcerative colitis (UC).